Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 1: Comparison with Sporadic Parathyroid Adenomas

A prospective study on the natural course of primary hyperparathyroidism has recently been reported. Since hyperparathyroidism in multiple endocrine neoplasia type 1 (MEN 1) is genetically distinct from most forms of sporadic hyperparathyroidism, it is important to know the natural course of hyperparathyroidism in MEN 1 for better clinical management. For this purpose, we retrospectively reviewed clinical parameters of patients with MEN 1 when they were diagnosed as having hyperparathyroidism, and compared them with those of patients with sporadic primary hyperparathyroidism. In patients with MEN 1: 1) levels of intact PTH (i-PTH) gradually increased with age, which accelerated over 40 years; 2) compared to the steep rise in i-PTH levels in aged patients, increase in serum calcium or decrease of serum inorganic phosphate concentration was relatively mild, and 3) the high concentrations of i-PTH in aged patients were not due to renal insufficiency. These features were not observed in patients with sporadic primary parathyroid adenomas. Clinical features of untreated hyperparathyroidism in MEN 1 may be significantly affected by the age of the patient. The effect, if any, of age-dependent deterioration on recurrence rate after subtotal or total parathyroidectomy requires further elucidation.

MEN1 Gene - Mutation - Parathyroid Hormone - Renal Function

References

• 1 Thakker R V. Multiple endocrine neoplasia - syndromes of the twentieth century.  J Clin Endocrinol Metab . 1998;  83 2617-2620
• 2 van Heerden J A, Kent R B, Sizemore G W, Grant C S, ReMine W H. Primary hyperparathyroidism in patients with multiple endocrine neoplasia syndromes.  Arch Surg. 1983;  118 533-536
• 3 Thompson N W. The surgical management of hyperparathyroidism and endocrine disease of the pancreas in the multiple endocrine neoplasia type 1.  J Intern Med. 1995;  238 269-280
• 4 Rizzoli R, Green J III, Marx S J. Primary hyperparathyroidism in familial multiple endocrine neoplasia type 1. Long-term follow-up of serum calcium levels after parathyroidectomy.  Am J Med. 1985;  78 467-474
• 5 Hellman P, Skogseid B, Öberg K, Juhlin C, Akerström G, Rastad J. Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1.  Surgery. 1998;  124 993-999
• 6 Burgess J R, David R, Parameswaran V, Greenaway T M, Shepherd J J. The outcome of subtotal parathyroidectomy for the treatment of hyperparathyroidism in multiple endocrine neoplasia type 1.  Arch Surg. 1998;  133 126-129
• 7 Chandrasekharappa S C, Guru S C, Manickam P, Olufemi S -E, Collins F S, Emmert-Buck M R, Debelenko L V, Zhuang Z, Lubensky I A, Liotta L A, Crabtree J S, Wang Y, Roe B A, Weisemann J, Boguski M S, Agarwal S K, Kester M B, Kim Y S, Heppner C, Dong Q, Spiegel A M, Burns AL and Marx S J. Positional cloning of the gene for multiple endocrine neoplasia-type 1.  Science. 1997;  276 404-407
• 8 Silverberg S J, Shane E, Jacobs T P, Siris E, Bilezikian J P. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.  N Engl J Med. 1999;  341 1249-1255
• 9 Katai M, Sakurai A, Itakura Y, Ikeo Y, Nakajima K, Hara M, Iijima S, Kaneko T, Kobayashi M, Ichikawa K, Aizawa T, Hashizume K. Multiple endocrine neoplasia type 1 is not rare in Japan.  Endocr J. 1997;  44 841-845
• 10 Sakurai A, Shirahama S, Fujimori M, Katai M, Itakura Y, Kobayashi S, Amano J, Fukushima Y, Hashizume K. Novel MEN1 gene mutations in familial multiple endocrine neoplasia type 1.  J Hum Genet. 1998;  43 199-201
• 11 Orwoll E S, Meier D E. Alterations in calcium, vitamin D, and parathyroid hormone physiology in normal men with aging: relationship to the development of senile osteopenia.  J Clin Endocrinol Metab. 1986;  63 1262-1269
• 12 Sherman S S, Hollis B W, Tobin J D. Vitamin D status and related parameters in a healthy population: the effects of age, sex and season.  J Clin Endocrinol Metab. 1990;  71 405-413
• 13 Prince R L, Dick I, Devine A, Price R I, Gutteridge D H, Kerr D, Criddle A, Garcia-Webb P, St John A. The effects of menopause and age on calcitropic hormones: a cross-sectional study of 655 healthy women aged 35 to 90.  J Bone Miner Res. 1995;  10 835-842
• 14 Bassett J HD, Forbes S A, Pannett A AJ, Lloyd S E, Christie P T, Wooding C, Harding B, Besser G M, Edwards C R, Monson J P, Sampson J, Wass J AH, Wheeler M H, Thakker R V. Characterization of mutations in patients with multiple endocrine neoplasia type 1.<./TI>.  Am J Hum Genet. 1998;  62 232-244
• 15 Smogorzewski M, Tian J, Massry S G. Down-regulation of PTH-PTHrP receptor of heart in CRF: role of [Ca²⁺]i.  Kidney Int. 1995;  47 1182-1186
• 16 Morieux Y J, Denne M A, Bouizar Z, Urena P, de Vernejoul M C. Paridronate corrects the down-regulation of the renal parathyroid hormone (PTH)/PTH-related peptide (PTHrP) receptor mRNA in rats bearing Walker tumors.  Horm Metab Res. 1998;  30 249-255
• 17 Carling T, Rastad J, Ridefelt P, Gobl A, Hellman P, Öberg K, Rask L, Larsson C, Juhlin C, Åkerström G, Skogseid B. Hyperparathyroidism of multiple endocrine neoplasia type 1: candidate gene and parathyroid calcium sensing protein expression.  Surgery. 1995;  118 924-931
• 18 D’Amour P, Palardy J, Bahsali G, Mallette L E, DeLéan A, Lepage R. The modulation of circulating parathyroid hormone immunoheterogeneity in man by ionized calcium concentration.  J Clin Endocrinol Metab. 1992;  74 525-532
• 19 Heppner C, Kester M B, Agarwal S K, Debelenko L V, Emmert-Buck M R, Guru S C, Manickam P, Olufemi S -E, Skarulis M C, Doppman J L, Alexander R H, Kim Y S, Saggar S K, Lubensky I A, Zhuang Z, Liotta L A, Chandrasekharappa S C, Collins F S, Spiegel A M, Burns A L, Marx S J. Somatic mutation of the MEN1 gene in parathyroid tumors.  Nat Genet. 1997;  16 375-378
• 20 Farnebo F, The B T, Kytyölä S, Svensson A, Phelan C, Sandelin K, Thompson N W, Höög A, Weber G, Farnebo L -O, Larsson C. Alterations of the MEN1 gene in sporadic parathyroid tumors.  J Clin Endocrinol Metab. 1998;  83 2627-2630
• 21 Carling T, Correa P, Hessman O, Hedberg J, Skogseid B, Lindberg D, Rastad J, Westin G, Åkerström G. Parathyroid MEN 1 gene mutations in relation to clinical characteristics of nonfamilial primary hyperparathyroidism.  J Clin Endocrinol Metab. 1998;  83 2960-2963
• 22 Arnold A, Kim H G, Gaz R D, Eddy R L, Fukushima Y, Byers MG Shows T B, Kronenberg H M. Molecular cloning and chromosomal mapping of DNA rearranged with the parathyroid hormone gene in a parathyroid adenoma.  J Clin Invest. 1989;  83 2034-2040
• 23 Cryns V, Yi S M, Tahara E, Gaz R D, Arnold A. Frequent loss of chromosome arm 1p in parathyroid adenomas.  Genes Chromosome Cancer. 1995;  13 9-17
• 24 Tahara H, Smith A P, Gas R D, Cryns V L, Arnold A. Genomic localization of novel candidate tumor suppressor gene loci in human parathyroid adenomas.  Cancer Res. 1996;  56 599-605
• 25 Teh B T, Farnebo F, Kristoffersson U, Sundelin B, Cardinal J, Axelson R, Yap A, Epstein M, Heath H III, Cameron D, Larsson C. Autosomal dominant primary hyperparathyroidism and jaw tumor syndrome associated with renal hamartomas and cystic kidney disease: linkage to 1q21-q32 and loss of the wild type allele in renal hamartomas.  J Clin Endocrinol Metab. 1996;  81 4204-4211